LinkedIn Google+ Twitter Facebook

Carisome® Mechanism of Action

Loading the player ...

Carisome Microvesicle Technology is a versatile, proprietary blood-based technology that is being studied for its potential utility as an aid in the diagnosis of common cancers such as colon, breast, lung and prostate cancer.

This technology platform has been designed to identify and characterise cells from circulating microvesicles (cMVs) released in the blood that serve as a signaling device for cancer.

Visit the Carisome Microvesicle Technology section to learn more about this promising blood-based diagnostic technology from Caris Life Sciences®.